Alembic Pharma receives USFDA approval for Tadlafil

Alembic Pharmaceuticals has received final USFDA approval for Tadalafil tablets, indicated for the treatment of erectile dysfunction. The drug will be marketed in strengths of 2.5 mg, 5mg, 10mg and 20 mg.

The product is generic version of Eli Lilly and Company’s Cialis tablet. According to market estimates, Tadalafil Tablets have an estimated market size of $1.8 billion for twelve months ending December 2018.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.